REGN Stock Analysis: Regeneron Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 82.979m USD | 12M Return: 40.6% | US75886F1075 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 607M
EPS Trend: 55.9%
Qual. Beats: 1
Rev. Trend: 95.6%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines across a broad range of therapeutic areas, including eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, neurological and infectious diseases, rare diseases, and oncology. Its commercial portfolio includes EYLEA (for retinal conditions including wet age-related macular degeneration), Dupixent (atopic dermatitis and asthma), Libtayo (cutaneous squamous cell carcinoma), Praluent (high cholesterol), and Kevzara (rheumatoid arthritis).
The business model relies heavily on proprietary R&D platforms and a network of strategic collaborations with major partners, including Bayer (EYLEA), Alnylam (RNAi therapeutics), Intellia (CRISPR/Cas9 gene editing), Hansoh (dual GLP-1/GIP receptor programs), Tessera (gene editing for Alpha-1 antitrypsin deficiency), Telix (radiopharmaceuticals), and CytomX (conditionally-activated bispecific cancer therapies). The company was founded in 1988 and is headquartered in Tarrytown, New York.
- EYLEA sales face Vabysmo competition pressure
- Dupixent label expansions accelerate immunology revenue growth
- GLP-1 deal with Hansoh expands obesity pipeline exposure
| Net Income: 4.33b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.62 > 1.0 |
| NWC/Revenue: 83.14% < 20% (prev 92.81%; Δ -9.67% < -1%) |
| CFO/TA 0.11 > 3% & CFO 4.44b > Net Income 4.33b |
| Net Debt (-5.29b) to EBITDA (5.75b): -0.92 < 3 |
| Current Ratio: 3.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (106.8m) vs 12m ago -1.66% < -2% |
| Gross Margin: 84.86% > 18% (prev 85.57%; Δ -0.71% > 0.5%) |
| Asset Turnover: 38.86% > 50% (prev 37.19%; Δ 1.67% > 0%) |
| Interest Coverage Ratio: 94.25 > 6 (EBIT TTM 5.22b / Interest Expense TTM 55.4m) |
| A: 0.31 (Total Current Assets 18.4b - Total Current Liabilities 5.53b) / Total Assets 41.7b |
| B: 0.90 (Retained Earnings 37.6b / Total Assets 41.7b) |
| C: 0.13 (EBIT TTM 5.22b / Avg Total Assets 40.0b) |
| D: 3.17 (Book Value of Equity 31.7b / Total Liabilities 10.0b) |
| Altman-Z'' = 9.17 = AAA |
| DSRI: 1.07 (Receivables 6.57b/5.61b, Revenue 15.5b/14.2b) |
| GMI: 1.01 (GM 85.57% / 84.86%) |
| AQI: 0.99 (AQ_t 0.43 / AQ_t-1 0.43) |
| SGI: 1.09 (Revenue 15.5b / 14.2b) |
| TATA: -0.00 (NI 4.33b - CFO 4.44b) / TA 41.7b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of August 21, 2026, the stock is trading at USD 826.64 with a total of 596,425 shares traded. Over the past week, the price has changed by +2.68%, over one month by +23.13%, over three months by +27.37% and over the past year by +40.59%.
Current recommended Stop Loss: 800.40 (which is 3.2% or 1.3 ATR below the current price).
Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy REGN.
- StrongBuy: 14
- Buy: 5
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 833.7 | 0.8% |
P/E Trailing = 19.7639
P/E Forward = 17.6367
P/S = 5.3415
P/B = 2.6234
P/EG = 1.3672
Revenue TTM = 15.5b USD
EBIT TTM = 5.22b USD
EBITDA TTM = 5.75b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 37.8m USD (from shortTermDebt, last fiscal year)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 720.0m
Net Debt = -5.29b USD (calculated: Debt 2.71b - CCE 7.99b)
Enterprise Value = 77.7b USD (83.0b + Debt 2.71b - CCE 7.99b)
Interest Coverage Ratio = 94.25 (Ebit TTM 5.22b / Interest Expense TTM 55.4m)
EV/FCF = 22.06x (Enterprise Value 77.7b / FCF TTM 3.52b)
FCF Yield = 4.53% (FCF TTM 3.52b / Enterprise Value 77.7b)
FCF Margin = 22.67% (FCF TTM 3.52b / Revenue TTM 15.5b)
Net Margin = 27.86% (Net Income TTM 4.33b / Revenue TTM 15.5b)
Gross Margin = 84.86% ((Revenue TTM 15.5b - Cost of Revenue TTM 2.35b) / Revenue TTM)
Gross Margin QoQ = 86.56% (prev 81.43%)
Tobins Q-Ratio = 1.86 (Enterprise Value 77.7b / Total Assets 41.7b)
Interest Expense / Debt = 2.05% (Interest Expense 55.4m / Debt 2.71b)
Taxrate = 16.21% (837.3m / 5.17b)
NOPAT = 4.38b (EBIT 5.22b * (1 - 16.21%))
Current Ratio = 3.34 (Total Current Assets 18.4b / Total Current Liabilities 5.53b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 31.7b)
Debt / EBITDA = -0.92 (Net Debt -5.29b / EBITDA 5.75b)
Debt / FCF = -1.50 (Net Debt -5.29b / FCF TTM 3.52b)
Total Stockholder Equity = 31.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.83% (Net Income 4.33b / Total Assets 41.7b)
RoE = 13.81% (Net Income TTM 4.33b / Total Stockholder Equity 31.3b)
RoCE = 15.67% (EBIT 5.22b / Capital Employed (Equity 31.3b + L.T.Debt 1.99b))
RoIC = 12.34% (NOPAT 4.38b / Invested Capital 35.5b)
WACC = 7.69% (E(83.0b)/V(85.7b) * Re(7.88%) + D(2.71b)/V(85.7b) * Rd(2.05%) * (1-Tc(0.16)))
Discount Rate = 7.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.18 | Cagr: -3.27%
[DCF] Terminal Value 74.22% ; FCFF base≈3.65b ; Y1≈3.41b ; Y5≈3.12b
[DCF] Fair Price = 539.8 (EV 49.3b - Net Debt -5.29b = Equity 54.6b / Shares 101.1m; r=8.35% [WACC [floored]]; 5y FCF grow -8.39% → 2.50% )
EPS Correlation: 55.92 | EPS CAGR: 1.10% | SUE: 3.13 | # QB: 1
Revenue Correlation: 95.59 | Revenue CAGR: 5.78% | SUE: 2.76 | # QB: 1
EPS current Quarter (2026-09-30): EPS=16.05 | Chg30d=+23.51% | Revisions=+85% | Analysts=20
EPS current Year (2026-12-31): EPS=53.22 | Chg30d=+15.58% | Revisions=+89% | GrowthEPS=+20.1% | GrowthRev=+18.0%
EPS next Year (2027-12-31): EPS=50.38 | Chg30d=+5.58% | Revisions=-62% | GrowthEPS=+16.7% | GrowthRev=+8.4%
[Analyst] Revisions Ratio: +73% (up=41, down=5)